

Item 8.01. Other Events.

On June 4, 2018, TG Therapeutics, Inc. (the “Company”) issued a press release announcing updated clinical data from its ongoing Phase 2 study evaluating umbralisib (TGR-1202), the Company’s PI3K delta inhibitor, in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy presented during the 54th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference. Filed as Exhibit 99.2 and incorporated in this Item by reference are slides utilized at the Company’s Investor and Analyst event on June 3, 2018.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated June 4, 2018.

99.2 Slides from Analyst and Investor Event, dated June 3, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.
(Registrant)

Date: June 4, 2018

By: /s/ Sean A. Power
Sean A. Power
Chief Financial Officer